about
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV InfectionMulticenter Quality Control for the Detection of Hepatitis C Virus RNA in Seminal Plasma SpecimensPersistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analoguesX4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHIPolymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimenCD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatoryRecent HIV-1 infection contributes to the viral diffusion over the French territory with a recent increasing frequencyAn In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene ExpressionHIV-DNA in the genital tract of women on long-term effective therapy is associated to residual viremia and previous AIDS-defining illnesses.Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected childr[HIV-1 drug resistance in French infected-children: from newborn to adolescent]18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission.Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 studyLack of HPA-23 antiviral activity in HIV-infected patients without AIDS.Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.Human cytomegalovirus UL144 gene polymorphisms in congenital infections.Gag-Specific CD8 T-Cell Proliferation Is Associated With Higher Peripheral Blood Levels of Transforming Growth Factor-β and Gut-Homing T Cells in Youths Perinatally Infected With Human Immunodeficiency Virus-1: The ANRS-EP38-IMMIP Study.Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy.A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting.Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infectionGenotypic resistance profiles of HIV-2-treated patients in West Africa.Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda.Isolation of a new human retrovirus from West African patients with AIDS.New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA loadRestriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers.Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infectionIsolation of a new retrovirus in a patient at risk for acquired immunodeficiency syndrome.HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication.A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI StudyAssociation between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire.Towards an HIV cure: a global scientific strategyCD8 T-cells from most HIV-infected patients lack ex vivo HIV-suppressive capacity during acute and early infection.Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover.A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection
P50
Q22242256-06C6A561-F0F1-468D-8679-CC22FA825502Q27317216-6AA575E6-F723-48B4-B621-681F86C4A119Q27473329-63870CF8-68F8-4999-B532-8DDB71FFD5B3Q28373514-8AFC035F-85E3-4714-A39F-E9DF8557C45AQ28476667-5B7DD9E1-4A64-4CAB-8CDE-0CB5E13D259CQ28477151-6716D98C-EB35-4254-9795-6806D19E726BQ28477861-1A264545-9ADE-4F3A-94DC-276888AE379EQ28480667-441112A5-5EC5-4947-81A6-9558D0B99B68Q28546918-88393947-9FD8-4031-AF55-BE68005853DCQ31130557-F837A23C-FF5B-4716-BAD1-56940EB998C8Q33267065-E9BDDB51-11EB-44F6-85DC-EC170BAB26A3Q33272704-58592346-5660-4301-A029-A2C8281E2AF2Q33320539-613560DE-AE5F-473E-A300-261DA34BE12AQ33395678-05764AC6-2403-4E4E-84DE-DEA66B112B92Q33415148-4C508682-81B7-4FDF-B9E9-D52652753E99Q33417236-4EDAA8E5-0D87-4CA2-B64D-3FED0DA806B4Q33476165-B9AF378A-116C-433F-82E4-4B785511BBDCQ33592356-2824466D-B4CC-49DD-A272-59C3648C3563Q33629212-B6E109C1-22CB-4419-AB96-707CD4F9A97AQ33640197-799A2E79-A4FF-4D73-B85C-37B0A955DF50Q33745355-E567A93F-E3C3-4D2E-ABBF-4AB91E580979Q33775397-B07D2DA4-F36D-46DE-92CB-1737CB3927C7Q33856274-5C56F3DF-64CD-41D1-B4D8-CE8D50F2C7E1Q33880339-63C38829-7CDE-4F6C-B147-45EC30102E00Q33954546-23703C8A-9188-4E1B-B8F7-C3CCA4984C1EQ33972150-CFFFA335-0ABE-47BD-85E6-8F0F519FA05CQ34038984-14A3AB6B-26EF-4A7D-A567-8EEB30FE1101Q34058765-84B10E48-4ECC-4FA9-8368-DB7C3B5822B2Q34189960-139DFE9D-3BE7-4425-B52F-056D3D6825E5Q34190296-728BF111-A438-40AA-9D2B-F06365CD1019Q34250390-57DBF84A-D20C-4C81-942B-E4D3710B589FQ34448446-BC4281B3-CA15-4206-AC09-180B32AB9F19Q34485938-A0364447-3B45-471C-8F90-E5B3670C89BAQ34623149-C4A45968-4D5F-4731-AE3F-37516C784193Q34629153-F5A38B61-E767-4065-B7EE-0F8EA486682BQ34630565-09FFAFE2-8175-400C-9FFD-17B8E330506AQ34640562-168B32F7-22A4-4502-8E7B-6B0186897A47Q34652157-6488A953-5566-414E-9B05-926DFFC3F29EQ34692601-BEDA4704-82DD-4776-A3CE-47E31E227B21Q34731350-440D7EB5-7AE5-4511-9661-4AD32AF97F15
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
taighdeoir
@ga
viróloga francesa
@ast
հետազոտող
@hy
عالمة فيروسات فرنسية
@ar
name
Christine Rouzioux
@ast
Christine Rouzioux
@ca
Christine Rouzioux
@en
Christine Rouzioux
@es
Christine Rouzioux
@fr
Christine Rouzioux
@nl
Christine Rouzioux
@sl
Кристин Рузью
@ru
type
label
Christine Rouzioux
@ast
Christine Rouzioux
@ca
Christine Rouzioux
@en
Christine Rouzioux
@es
Christine Rouzioux
@fr
Christine Rouzioux
@nl
Christine Rouzioux
@sl
Кристин Рузью
@ru
prefLabel
Christine Rouzioux
@ast
Christine Rouzioux
@ca
Christine Rouzioux
@en
Christine Rouzioux
@es
Christine Rouzioux
@fr
Christine Rouzioux
@nl
Christine Rouzioux
@sl
Кристин Рузью
@ru
P214
P269
P101
P106
P1412
P21
P213
0000 0001 4083 1966
P214
P269
P27
P31
P3956
P569
1950-06-25T00:00:00Z
P735
P7859
viaf-208981144